- support
- info@evidentic.com
- +49 (0) 30 959 99 8831
Aliquots are pre-aliquoted, commercially available drugs from the EU. Our aliquots thus contain therapeutic molecules manufactured by the original drug license holder and repackaged by Evidentic.
ProductBatch | Antigen | Molecular Class | Drug Brand | Product Concentration | CoA | Quantity per vial | Storage Temperature | Expiry Date | Price from | |
---|---|---|---|---|---|---|---|---|---|---|
C5 complement protein |
Biosimilar , Monoclonal Antibody |
Bekemv® |
10 mg/mL |
– |
3 mg |
tba |
tba |
391,00 € |
||
C5 complement protein |
Biosimilar , Monoclonal Antibody |
Epysqli® |
10 mg/mL |
– |
3 mg |
tba |
tba |
391,00 € |
||
C5 complement protein |
Monoclonal Antibody |
Soliris® |
10 mg/mL |
yes |
4 mg |
-80°C |
04/2022 |
652,50 € |
||
Fc Receptor (FcRn) |
Antibody Fab'fragment |
Vyvgart® |
20 mg/mL |
– |
20 mg |
-80 °C |
04/2025 |
1.959,00 € |
||
Fc Receptor (FcRn) |
Antibody Fab'fragment |
Vyvgart® |
20 mg/mL |
– |
5 mg |
-80 °C |
04/2024 |
784,00 € |
||
SLAMF7 |
Monoclonal Antibody |
Empliciti® |
25 mg/mL |
– |
6 mg |
-80 °C |
09/2022 |
243,00 € |
||
SLAMF7 |
Monoclonal Antibody |
Empliciti® |
25 mg/mL |
– |
6 mg |
-80°C |
02/2024 |
243,00 € |
||
Clotting Factor IXa and X |
Bispecific Antibody |
Hemlibra® |
30 mg/mL |
– |
2 mg |
-80°C |
09/2023 |
654,30 € |
||
Clotting Factor IXa and X |
Bispecific Antibody |
Hemlibra® |
30 mg/mL |
– |
2 mg |
-80°C |
08/2024 |
727,00 € |
||
Nect |
Antibody-drug conjugate (ADC) |
Padcev® |
10 mg/mL |
– |
1 mg |
tba |
tba |
329,00 € |
||
EPO receptor |
Biosimilar , Glycoprotein hormone |
Silapo® |
40000 IU/mL |
– |
5000 IU |
-80°C |
08/2022 |
336,60 € |
||
α- and β- CGPR |
Monoclonal Antibody |
Vyepti® |
100 mg/mL |
– |
4 mg |
tba |
tba |
304,00 € |
||
TNF alpha |
Biosimilar , Fusion protein |
Erelzi® |
50 mg/mL |
– |
4 mg |
-80°C |
04/2023 |
237,60 € |
||
TNF alpha |
Fusion protein |
Enbrel® |
50 mg/mL |
– |
6 mg |
-80°C |
01/2024 |
239,40 € |
||
TNF alpha |
Biosimilar , Fusion protein |
Benepali® |
50 mg/mL |
– |
4 mg |
-80°C |
11/2023 |
237,60 € |
||
TNF alpha |
Fusion protein |
Enbrel® |
25 mg/mL |
– |
2 mg |
-80°C |
02/2019 |
171,90 € |
||
TNF alpha |
Fusion protein |
Enbrel® |
50 mg/mL |
– |
2 mg |
-80°C |
04/2019 |
171,90 € |
||
TNF alpha |
Fusion protein |
Enbrel® |
50 mg/mL |
– |
2 mg |
-80°C |
06/2019 |
171,90 € |
||
TNF alpha |
Fusion protein |
Enbrel® |
50 mg/mL |
– |
2 mg |
-80°C |
08/2019 |
171,90 € |
||
TNF alpha |
Fusion protein |
Enbrel® |
25 mg/mL |
– |
2 mg |
-80°C |
12/2019 |
171,90 € |
||
TNF alpha |
Fusion protein |
Enbrel® |
50 mg/mL |
– |
2 mg |
-80°C |
10/2019 |
171,90 € |
||
TNF alpha |
Fusion protein |
Enbrel® |
50 mg/mL |
– |
2 mg |
-80°C |
04/2020 |
171,90 € |
||
TNF alpha |
Biosimilar , Fusion protein |
Nepexto® |
50 mg/mL |
– |
4 mg |
-80 °C |
08/2023 |
|||
ANGPTL3 |
Monoclonal Antibody |
Evkeeza® |
150 mg/mL |
– |
7.5 mg |
tba |
tba |
1.088,00 € |
||
PCSK9 |
Monoclonal Antibody |
Repatha® |
140 mg/mL |
– |
3,5 mg |
-80 °C |
06/2025 |
135,00 € |
||
VEGF-A |
Monoclonal Antibody |
Vabysmo® |
120 mg/mL |
– |
2.4 mg |
tba |
tba |
618,00 € |
||
Dermatan sulfate , Perilipin-3 |
Enzyme |
Naglazyme® |
1,0 mg/mL |
– |
0,2 mg |
-80°C |
07/2023 |
493,20 € |
||
CD33 |
Antibody-drug conjugate (ADC) |
Mylotarg® |
1 mg/mL |
– |
0,1 mg |
-80°C |
08/2024 |
1.127,00 € |
||
CD33 |
Antibody-drug conjugate (ADC) |
Mylotarg® |
1 mg/mL |
– |
0,1 mg |
-80°C |
03/2025 |
1.127,00 € |
||
CD20 , CD3 |
Bispecific Antibody |
Columvi® |
1 mg/mL |
– |
0,1 mg |
tba |
tba |
390,00 € |
Evidentic GmbH
Martin-Buber-Str. 10
14163 Berlin